satralizumab

Neuromyelitis Optica Spectrum Disorder (NMOSD)

Satralizumab is used to treat neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune disease that affects the central nervous system. In people with NMOSD, the immune system attacks the optic nerves and the spinal cord, which can cause inflammation, vision loss, and problems with muscle coordination or movement.

Specific Patient Requirements

This medication is only approved for use in adults who are anti-aquaporin-4 (AQP4) antibody positive. Before starting treatment, a healthcare provider will use a blood test to confirm the presence of these specific antibodies. Satralizumab is not indicated for patients who do not have these antibodies.

Purpose of Treatment

The main goal of using satralizumab is to reduce the frequency of relapses, which are also called attacks or flares. By preventing these episodes, the medication helps manage the long-term progression of the disease. It is important to note the following regarding its use:

• It is used as a long-term maintenance therapy.
• It is not used to treat an active NMOSD attack while it is happening.
• It helps prevent future damage to the nervous system by targeting specific parts of the immune response.

Mechanism of Action

Satralizumab belongs to a class of medications known as interleukin-6 (IL-6) receptor antagonists. In people with neuromyelitis optica spectrum disorder (NMOSD), the immune system mistakenly attacks healthy cells in the optic nerves and spinal cord. This process is driven in part by a protein called interleukin-6, which triggers inflammation and immune system activity.

This medication works by:

• Binding to receptors: Satralizumab attaches to specific receptors on the surface of cells and in the bloodstream.
• Blocking signals: By binding to these receptors, it prevents interleukin-6 from sending signals that cause inflammation.
• Reducing attacks: Lowering this inflammatory response helps decrease the frequency and severity of NMOSD relapses.

By controlling the overactive immune response, satralizumab helps protect the nerves from damage caused by the body's own defense system.

Common Side Effects

• Headache
• Joint pain
• Common cold symptoms, such as a sore throat or runny nose
• Rash
• Fatigue
• Nausea or stomach pain (gastritis)
• Pain in the arms or legs
• Injection site reactions, including redness, itching, pain, or swelling

Serious Side Effects

Contact a healthcare provider immediately if you experience any of the following serious side effects:

• Infections: Fever, chills, cough, or painful urination. Satralizumab can increase the risk of serious infections like pneumonia or cellulitis.
• Liver problems: Yellowing of the skin or eyes (jaundice), dark urine, or pain in the upper right side of the stomach.
• Low white blood cell counts: This may be detected through blood tests and can make it harder for your body to fight infections.
• Allergic reactions: Hives, swelling of the face, lips, or tongue, or difficulty breathing.

Infections

Satralizumab can increase the risk of serious infections. Treatment is typically not started in individuals with an active infection. Healthcare providers screen for tuberculosis (TB) and hepatitis B before beginning therapy. If a person has a history of hepatitis B or is a carrier, the virus may become active again during treatment.

Liver Enzyme Monitoring

This medication may cause elevations in liver enzymes, which can indicate liver stress or injury. Blood tests to check liver function are usually performed before starting the drug and periodically during treatment.

Blood Count Changes

A decrease in the number of neutrophils, a type of white blood cell that fights infection, may occur. Regular blood tests are used to monitor these levels throughout the course of treatment.

Vaccinations

Live or live-attenuated vaccines should be avoided while using satralizumab. It is generally recommended that all necessary vaccinations be completed at least four weeks before starting the medication.

Hypersensitivity Reactions

Allergic reactions can occur with this medication. Signs of a serious reaction may include rash, swelling, or difficulty breathing, which require immediate medical attention.

Pregnancy

It is not yet known if satralizumab will harm an unborn baby. While animal studies have not shown harmful effects on the fetus, there is not enough data from human studies to confirm its safety. As a monoclonal antibody, satralizumab is likely to cross the placenta during pregnancy.

Individuals who are pregnant or planning to become pregnant should consult with their healthcare provider to weigh the potential benefits of treatment against any possible risks.

Breastfeeding

It is unknown if satralizumab passes into breast milk or if it could affect a nursing infant or milk production. Because the risks are not well understood, it is recommended to discuss breastfeeding plans with a doctor before starting or continuing treatment.

Dosage Forms

Satralizumab is supplied in the following form:

• Injection: A clear, colorless to slightly yellow liquid solution.

Administration Method

This medication is designed for subcutaneous use, meaning it is injected into the fatty tissue just beneath the skin. It is provided in a single-dose prefilled syringe intended for one-time use.

FDA Approval and Indications

The U.S. Food and Drug Administration (FDA) approved satralizumab in August 2020. It is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive. It was the first subcutaneous treatment approved for this condition that can be administered by a patient or caregiver at home after training.

Regulatory Requirements and Screenings

Because satralizumab affects the immune system, the FDA-approved labeling requires healthcare providers to complete several screenings before a patient begins treatment:

• Antibody Testing: Patients must test positive for the AQP4 antibody, as the medication's effectiveness has not been established in patients who are antibody-negative.
• Hepatitis B Screening: Providers must test for Hepatitis B virus (HBV) infection before starting the first dose.
• Tuberculosis Screening: Patients must be evaluated for active or latent tuberculosis (TB) infection.
• Vaccinations: All required immunizations should be completed according to current guidelines before starting therapy.

Satralizumab does not currently carry a boxed warning or a Risk Evaluation and Mitigation Strategy (REMS) requirement. It is available only by prescription.

Factors Affecting Cost

The out-of-pocket cost for satralizumab is influenced by several factors:

• Insurance Coverage: Your specific health plan, including your deductible and copayment or coinsurance amounts, will determine how much you pay.
• Prior Authorization: Most insurance providers require a prior authorization process. This means your doctor must provide documentation to your insurance company to prove the medication is medically necessary before they will cover the cost.
• Specialty Pharmacy: Satralizumab is a specialty medication and is typically dispensed through specialty pharmacies rather than standard retail pharmacies, which can affect pricing and delivery.

Generic and Biosimilar Availability

There is currently no generic or biosimilar version of satralizumab available. As a biologic medication, it is protected by patents that prevent other companies from making lower-cost versions for a set period of time.

Financial Assistance

The manufacturer may offer support programs to help patients manage the cost of the medication. These may include:

• Copay Cards: Eligible patients with commercial insurance may be able to use a copay card to reduce their monthly out-of-pocket expenses.
• Patient Assistance Programs: Individuals who are uninsured or underinsured may qualify for programs that provide the medication at a reduced cost or for free, based on financial need.

It is recommended to speak with your healthcare provider or contact your insurance company directly to understand the specific costs associated with your treatment plan.